Get the Stockscreener App
1,051.99
2.93%
29.97
After Hours:
1048.25
-3.74
-0.36%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,051.99, with a volume of 4.31M.
It is up +2.93% in the last 24 hours and up +1.20% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,022.02
Open:
$1019.17
24h Volume:
4.31M
Relative Volume:
1.32
Market Cap:
$992.40B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
46.57
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
+4.21%
1M Performance:
+1.20%
6M Performance:
+43.29%
1Y Performance:
+16.22%
1-Day Range:
$1,017.36
$1,053.00
1-Week Range:
$1,007.38
$1,064.45
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,051.99 | 964.13B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
248.43 | 586.74B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
232.08 | 397.29B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
208.45 | 316.32B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
168.62 | 315.82B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave - The Economic Times
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company
Laurel Wealth Advisors LLC Lowers Stake in Eli Lilly and Company $LLY - MarketBeat
Finemark National Bank & Trust Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Artisan Partners Limited Partnership Grows Stock Position in Eli Lilly and Company $LLY - MarketBeat
Ibex Wealth Advisors Sells 5,897 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Bought by Power Wealth Management LLC - MarketBeat
Eli Lilly and Company $LLY Position Boosted by Clal Insurance Enterprises Holdings Ltd - MarketBeat
American Century Companies Inc. Acquires 120,905 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (NYSE:LLY) Trading Up 2.8% Following Analyst Upgrade - MarketBeat
Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable (NYSE:NVO) - Seeking Alpha
Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle - Fierce Biotech
The New Magnificent Stocks to Own in 2026 - Investing.com
Eli Lilly launches LillyPod, pharma's most powerful supercomputer - R&D World
Is the Market Bullish or Bearish on Eli Lilly and Co? - Benzinga
Lilly’s Olumiant receives positive EU opinion for adolescent alopecia - Investing.com
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Eli Lilly and Company $LLY Position Decreased by MGB Wealth Management LLC - MarketBeat
Handelsbanken Fonder AB Purchases 92,689 Shares of Eli Lilly and Company $LLY - MarketBeat
Generali Investments Management Co LLC Acquires 3,281 Shares of Eli Lilly and Company $LLY - MarketBeat
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500 - 富途牛牛
Eli Lilly and Company $LLY Shares Sold by FUKOKU MUTUAL LIFE INSURANCE Co - MarketBeat
Lilly unveils supercomputer to expand AI drug discovery push - The Pharma Letter
Close Asset Management Ltd Has $43.54 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly, Nvidia Launch LillyPod: Pharma’s First ‘AI Factory’ in Indianapolis - TipRanks
Navigating Price Competition: Eli Lilly's Strategic Position in the Weight-Loss Drug Market - AD HOC NEWS
1ST Source Bank Sells 983 Shares of Eli Lilly and Company $LLY - MarketBeat
RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market - Finviz
Lilly’s Orforglipron Tops Novo’s Semaglutide In Diabetes Trial - Citeline News & Insights
Friday Five – Novo's no-go week, tolerability tempers Lilly's oral edge, GSK makes pulmonary hypertension play…and more - FirstWord Pharma
Now Live: The World’s Most Powerful AI Factory for Pharmaceutical Discovery and Development - NVIDIA Blog
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 - Benzinga
Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet - Investing News Network
Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus
Latest Research: Eli Lilly and Co's Oral Weight-Loss Drug Orforglipron Demonstrates Superior Weight Loss Effects Compared to Semaglutide Tablets - 富途牛牛
Building permit issued for $77M expansion at Eli Lilly manufacturing campus in Concord - The Business Journals
Eli Lilly and Company GLP-1 pill outperforms rival in type 2 diabetes trial - Traders Union
Eli Lilly's weight-loss pill shows higher side effects than Novo rival in diabetes trial - Reuters
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company - Eli Lilly and Company
Eli Lilly Shares Weather Competitive Pricing Move - AD HOC NEWS
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy HQ - Inside INdiana Business
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus - Indianapolis Business Journal
Eli Lilly Prevails in Appeal of Licensor’s Drug Royalty Claim - Bloomberg Law News
9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case - Law360
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics - The Chronicle-Journal
Eli Lilly Strengthens Market Leadership as Rival Stumbles - AD HOC NEWS
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - aol.com
Assessing Eli Lilly: Insights From 13 Financial Analysts - Benzinga
Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market - thestreet.com
Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study - Finviz
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):